ProShare Advisors’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-24,659
| Closed | -$535K | – | 1438 |
|
|
2017
Q2 | $535K | Sell |
24,659
-1,744
| -7% | -$31.7K | 0.01% | 939 |
|
|
2017
Q1 | $370K | Sell |
26,403
-6,602
| -20% | -$108K | ﹤0.01% | 1144 |
|
|
2016
Q4 | $619K | Buy |
33,005
+2,956
| +10% | +$50.2K | 0.01% | 974 |
|
|
2016
Q3 | $496K | Sell |
30,049
-317
| -1% | -$4.7K | 0.01% | 959 |
|
|
2016
Q2 | $408K | Buy |
30,366
+413
| +1% | +$6.03K | 0.01% | 1055 |
|
|
2016
Q1 | $458K | Sell |
29,953
-2,902
| -9% | -$45.5K | 0.01% | 1038 |
|
|
2015
Q4 | $652K | Buy |
32,855
+2,931
| +10% | +$55.7K | 0.01% | 926 |
|
|
2015
Q3 | $521K | Sell |
29,924
-127
| -0.4% | -$2.59K | 0.01% | 924 |
|
|
2015
Q2 | $608K | Sell |
30,051
-1,424
| -5% | -$27.5K | 0.01% | 1012 |
|
|
2015
Q1 | $554K | Buy |
31,475
+4,312
| +16% | +$73.5K | 0.01% | 1126 |
|
|
2014
Q4 | $442K | Buy |
27,163
+571
| +2% | +$10.5K | 0.01% | 1263 |
|
|
2014
Q3 | $587K | Sell |
26,592
-5,157
| -16% | -$106K | 0.01% | 1311 |
|
|
2014
Q2 | $639K | Sell |
31,749
-15,980
| -33% | -$271K | 0.01% | 1429 |
|
|
2014
Q1 | $887K | Buy |
47,729
+32,071
| +205% | +$442K | 0.01% | 1402 |
|
|
2013
Q4 | $158K | Sell |
15,658
-10,209
| -39% | -$123K | ﹤0.01% | 1274 |
|
|
2013
Q3 | $333K | Buy |
+25,867
| New | +$318K | 0.01% | 1816 |
|
Other funds holding AMRI
ProShare Advisors's AMRI Position: Q3 2017 in Review
ProShare Advisors sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 24,659 shares — an estimated $535K sold.
ProShare Advisors first reported a position in AMRI in Q3 2013 and held it in 16 quarters. The position peaked at $887K in Q1 2014. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- ProShare Advisors reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- ProShare Advisors sold 24,659 Albany Molecular Research Inc shares in Q3 2017, an estimated $535K.
- ProShare Advisors first reported a position in Albany Molecular Research Inc in Q3 2013 and held it in 16 quarters.
- ProShare Advisors's Albany Molecular Research Inc position peaked at $887K in Q1 2014.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on ProShare Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.